These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
309 related articles for article (PubMed ID: 9549921)
1. Cytoskeletal reorganization after preparation of platelet concentrates, using the buffy coat method, and during their storage. Estebanell E; Diaz-Ricart M; Lozano M; Mazzara R; Escolar G; Ordinas A Haematologica; 1998 Feb; 83(2):112-7. PubMed ID: 9549921 [TBL] [Abstract][Full Text] [Related]
2. Cytoskeletal changes in platelets induced by thrombin and phorbol myristate acetate (PMA). Chen R; Liang N Cell Biol Int; 1998; 22(6):429-35. PubMed ID: 10328851 [TBL] [Abstract][Full Text] [Related]
3. Effects of storage conditions on platelet cytoskeletal proteins. Prodouz KN; Moroff G J Lab Clin Med; 1985 May; 105(5):560-7. PubMed ID: 3989348 [TBL] [Abstract][Full Text] [Related]
4. Platelet activation of platelet concentrates derived from buffy coat and apheresis methods. Ali SF Transfus Apher Sci; 2011 Feb; 44(1):11-3. PubMed ID: 21277261 [TBL] [Abstract][Full Text] [Related]
5. Quality analysis of blood components obtained by automated buffy-coat layer removal with a top & bottom system (Optipress (R)II). Hurtado C; Bonanad S; Soler Mf; Mirabet V; Blasco I; Planelles Mf; De Miguel A Haematologica; 2000 Apr; 85(4):390-5. PubMed ID: 10756365 [TBL] [Abstract][Full Text] [Related]
6. Effects of cytochalasin H, a potent inhibitor of cytoskeletal reorganisation, on platelet function. Natarajan P; May JA; Sanderson HM; Zabe M; Spangenberg P; Heptinstall S Platelets; 2000 Dec; 11(8):467-76. PubMed ID: 11177446 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Impact-R for monitoring the platelet storage lesion. Albanyan AM; Murphy MF; Harrison P Platelets; 2009 Feb; 20(1):1-6. PubMed ID: 19172514 [TBL] [Abstract][Full Text] [Related]
8. [Analysis of the quality of hemoderivatives obtained using a buffy-coat extraction system with a top-and-bottom technique (Optipress II)]. Hurtado C; Bonanad S; Soler MA; Mirabet V; Blasco I; Planelles MD; de Miguel A Sangre (Barc); 1999 Oct; 44(5):319-26. PubMed ID: 10618907 [TBL] [Abstract][Full Text] [Related]
9. Platelet products prepared by different methods of sedimentation undergo platelet activation differently during storage. Skripchenko A; Kurtz J; Moroff G; Wagner SJ Transfusion; 2008 Jul; 48(7):1469-77. PubMed ID: 18482181 [TBL] [Abstract][Full Text] [Related]
10. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates. Edvardsen L; Taaning E; Dreier B; Christensen LD; Mynster T; Nielsen HJ Am J Hematol; 2001 Jul; 67(3):157-62. PubMed ID: 11391711 [TBL] [Abstract][Full Text] [Related]
11. Markers of platelet activation and apoptosis in platelet concentrates collected by apheresis. Procházková R; Andrýs C; Hubácková L; Krejsek J Transfus Apher Sci; 2007 Oct; 37(2):115-23. PubMed ID: 17945536 [TBL] [Abstract][Full Text] [Related]
12. The composition of the platelet cytoskeleton following activation by ADP: effects of various agents that modulate platelet function. May JA; Glenn JR; Spangenberg P; Heptinstall S Platelets; 1996; 7(3):159-68. PubMed ID: 21043595 [TBL] [Abstract][Full Text] [Related]
13. [Blood fractionation based on the extraction of the buffy-coat layer. Analysis of our results]. Algora M; Torres P; Rodríguez MA; de la Calle C; Biurrún M; Nieto S; Ruiz M; Alonso MV Sangre (Barc); 1995 Apr; 40(2):91-6. PubMed ID: 7784953 [TBL] [Abstract][Full Text] [Related]
14. Immunoelectron microscopic localization of actin, alpha-actinin, actin-binding protein and myosin in resting and activated human blood platelets. Sixma JJ; van den Berg A; Jockusch BM; Hartwig J Eur J Cell Biol; 1989 Apr; 48(2):271-81. PubMed ID: 2744001 [TBL] [Abstract][Full Text] [Related]
15. The quality of platelet concentrates produced by COBE Spectra and Trima Accel cell separators during storage for 7 days as assessed by in vitro methods. Tynngård N; Lindahl TL; Trinks M; Studer M; Berlin G Transfusion; 2008 Apr; 48(4):715-22. PubMed ID: 18208416 [TBL] [Abstract][Full Text] [Related]
16. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products. Li J; de Korte D; Woolum MD; Ruane PH; Keil SD; Lockerbie O; McLean R; Goodrich RP Vox Sang; 2004 Aug; 87(2):82-90. PubMed ID: 15355498 [TBL] [Abstract][Full Text] [Related]
17. Alterations in cytoskeletal organization and tyrosine phosphorylation in platelet concentrates prepared by the buffy coat method. Estebanell E; Díaz-Ricart M; Escolar G; Lozano M; Mazzara R; Ordinas A Transfusion; 2000 May; 40(5):535-42. PubMed ID: 10827255 [TBL] [Abstract][Full Text] [Related]
18. Analysis of platelet cytoskeleton assembly during platelet activation in Hermansky-Pudlak syndrome and thrombasthenia. Fujimura K; Fujimoto T; Takemoto M; Oda K; Shimomura T; Maehama S; Kuramoto A Thromb Haemost; 1990 Feb; 63(1):103-11. PubMed ID: 2339346 [TBL] [Abstract][Full Text] [Related]
19. External calcium facilitates signalling, contractile and secretory mechanisms induced after activation of platelets by collagen. Arderiu G; Pérez-Pujol S; Escolar G; White JG; Díaz-Ricart M Platelets; 2008 May; 19(3):172-81. PubMed ID: 18432518 [TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. Moog R; Fröhlich A; Mayaudon V; Lin L J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]